Cigarettes with ultralow nicotine levels are now being called the game-changer in the fight against smoking. If you are having trouble in quitting smoking, then, it is for you, that soon the Biden White House is expected to formally propose a plan that will order cigarette nicotine levels to be reduced, reports The Washington Post. For now though, it has been a failure, as these cigarettes, also known as VLN cigarettes that stands for very low nicotine are only available in 5,100 stores in 26 states. This is a very small fraction of the overall market for cigarettes. The company that makes it, 22nd Century, is struggling not because of the low supply, but also from the advocates who have long believed slashing nicotine levels altogether.
Nicotine is a chemical that is produced naturally from tobacco that makes the cigarette and also keeps people hooked. While it is believed that it makes people alert, and get the "hit" to keep them going, it exposes the users to harmful substances, carcinogens, and increases the risk of heart disease, lung cancer, and other illness.
Ultralow-nicotine cigarettes, like the VLN brand, contain about 95% less nicotine than the regular cigarettes. The idea is quite simple: without the addictive grip of nicotine, smokers will find it easier to quit. Research too has shown some promise. For instance, the studies funded by the National Institute on Drug Abuse revealed that very low nicotine cigarettes reduced addiction potential significantly without having users to increase their smoking frequency. However, the problem is, why would anyone choose for a low-nicotine that does not make them feel the same way, when the high-nicotine cigarette is right next to it, making them feel the same way, with the same alertness, sold at the same price.
“It’s very hard to imagine someone actively choosing to continue to use a low-nicotine product for the same price when a high-nicotine product is right next to it,” said Eric Donny, a Wake Forest University School of Medicine nicotine researcher.
No wonder, the experiment with low nicotine product by Philip Morris' Next cigarettes in the 1980s and Vector Tobacco's Quest brand in the early 2000s, flopped.
The Food and Drug Administration (FDA) has supported the development of such products, even allowing VLN cigarettes to be marketed as lower-risk options. However, these products remain a niche market, available in only a fraction of U.S. stores.
Recently, the Biden administration has considered a bold step—mandating a dramatic reduction in nicotine levels for all cigarettes sold in the United States. Supporters believe this move could save millions of lives, while critics, including tobacco companies, warn of potential unintended consequences.
Resistance from Big Tobacco Companies: They could argue that slashing nicotine levels could backfire. Their claim is, smokers will turn to black markets or smoke more to satisfy their cravings, which may lead to greater exposure to harmful substances.
Consumer Reluctance: History is proof to the instances of smokers being hesitant to embrace the low-nicotine products.
Political Hurdle: It may face political roadblocks, as under the Trump administration, plans to cut nicotine were shelved.
Advocates believe that ultralow-nicotine cigarettes could be a game-changer, comparing them to decaf coffee or non-alcoholic beer—products that reduce harm while offering a similar experience.
Some experts warn that a black market for traditional cigarettes could undermine these efforts. They also stress the need for safer alternatives, such as vaping products, to support smokers transitioning away from traditional cigarettes.
Credit: AI
Louisiana health officials have confirmed a rare infection caused by Naegleria fowleri, commonly called the “brain-eating amoeba,” in a resident who most likely contracted the infection after swimming in Lake Claiborne in Louisiana.
The Louisiana Department of Health confirmed the case this week, issuing a warning to people entering warm freshwater. It is the fourth documented Naegleria fowleri infection in Louisiana since 1937.
The case comes as health officials continue to warn about the seasonal risk of the amoeba, which thrives in warm freshwater, particularly during the summer months. According to CDC data, most US cases occur in July and August.
From the nasal pathway, the organism can travel along the olfactory nerves into the brain and cause primary amebic meningoencephalitis (PAM), an infection that progresses rapidly and causes inflammation and destruction of brain tissue.
Swallowing contaminated water also does not cause Naegleria infection, and the infection cannot spread from one person to another.
Also read: Fournier Gangrene: Woman Develops Rare Flesh-eating Infection After Bikini Shave, Herbal Application
Naegleria fowleri is naturally found in warm freshwater lakes, ponds and rivers, as well as some hot springs and other warm-water environments.
According to CIDRAP, the amoeba can survive at temperatures as high as about 115°F (46°C). Cases are particularly linked with freshwater exposure during periods of high temperatures.
The risk remains extremely low despite its potentially devastating outcome. The CDC recorded 180 PAM cases in the US from 1937 through 2025, with cases ranging from zero to eight per year.
The LDH said recreational water users should not assume that warm freshwater is completely risk-free. “Though the risk of infection is low, recreational water users should always assume there is a risk when they enter warm fresh water.”
The department added that people can reduce their risk by preventing water from entering your enters the nose. That can include using nose clips or keeping the nose above water when swimming in warm freshwater.
Primary amebic meningoencephalitis can initially mimic other infections. Early symptoms can include headache, fever, nausea and vomiting. As the infection progresses, patients can develop a stiff neck, confusion, problems with balance, seizures, hallucinations and loss of consciousness.
The illness progresses extremely quickly, with CDC data indicating that symptoms generally begin within 1 to 12 days after exposure. Death can occur within days after symptoms appear. As the disease is extremely rare and its early symptoms resemble other forms of meningitis, diagnosis can be challenging.
The Louisiana case follows another recent case in the state involving an 8-year-old Ruston girl, who was hospitalized after developing a Naegleria fowleri infection that health officials said may have been acquired while swimming in a North Louisiana lake.
The cases highlight the importance of taking precautions around warm freshwater during the summer, even though the overall probability of infection remains extremely small.
The CDC recommends avoiding activities in warm freshwater when possible, particularly during periods of high water temperatures. People who do enter such water can reduce exposure by using nose clips or keeping their head above water, and by avoiding stirring up sediment in shallow, warm areas.
Another important precaution concerns nasal rinsing. Naegleria can also be transmitted when contaminated tap water is used in devices such as neti pots. For nasal rinsing, the CDC recommends using distilled or sterile water, or water that has been boiled and cooled.
Credit: iStock
Amid an ongoing Salmonella outbreak that has infected hundreds of people, vulnerable groups in the UK are being advised to avoid undercooked or runny eggs.
The Food Standards Agency (FSA) issued the precautionary advice after the UK Health Security Agency (UKHSA) declared a national outbreak. The outbreak has infected 207 people across the UK, with one death and 34 hospitalisations.
Officials suspect imported eggs or food products containing imported eggs may be behind the outbreak.
However, the FSA said well-cooked eggs served in restaurants, cafes and takeaways are safe to eat.
Who Is at Risk?
The FSA advised vulnerable groups, including:
Ian Young, chief scientific adviser at the FSA, said vulnerable people eating out should ensure that eggs and egg products are thoroughly cooked.
Which Foods Should Be Avoided?
The FSA advised vulnerable people to avoid runny eggs and freshly made foods that may contain uncooked eggs, including:
Are Supermarket Eggs Safe?
Young reiterated that people can continue to buy British eggs from supermarkets. Chickens bred in the UK are vaccinated against common strains of Salmonella.
“There is no link to those eggs to this current outbreak,” he said.
He described the outbreak as “unusually large and rapidly increasing” and urged people to take precautions.
The UKHSA has launched an investigation to identify the source of the outbreak. Initial findings suggest it may be linked to eggs imported from outside the UK, although the source has not yet been definitively established.
Dr Kathleen O'Reilly, associate professor at the London School of Hygiene & Tropical Medicine, said the investigation involves identifying additional cases and examining possible common sources of infection.
Where Have Cases Been Reported?
Cases have been reported across the UK:
In England, London has reported the highest number of cases, with 47, followed by Yorkshire and the Humber with 38.
What Is Salmonella?
Salmonella is a bacterial infection that commonly causes diarrhoea and gastrointestinal illness.
Common symptoms include:
How Does Salmonella Spread?
The UKHSA stated that Salmonella Enteritidis is the most common Salmonella serovar in England and a leading cause of salmonellosis.
Like other non-typhoidal Salmonella infections, it can spread through contaminated food, including:
The bacteria can also spread through contact with contaminated environments or from person to person.
How to Reduce the Risk of Salmonella
Dr O'Reilly advised people to fully cook eggs before eating them and maintain good food hygiene.
Key precautions include:
People who develop diarrhoea or stomach cramps should rest and drink plenty of fluids. Young children, older adults and other vulnerable people who become ill should seek medical advice.
Credit: iStock
Moderna and Merck’s personalized mRNA cancer vaccine has shown statistically significant and clinically meaningful improvements. The late-stage trial showed recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) when combined with Keytruda in patients with melanoma, an aggressive form of skin cancer.
The vaccine, intismeran autogene (mRNA-4157/V940), is custom-made for each patient based on the unique genetic characteristics of their tumor. It is designed to work alongside Keytruda (pembrolizumab), an immunotherapy that helps the immune system attack cancer cells.
According to experts, the development moves personalized cancer therapy closer to a practical clinical reality.
“A tumor-specific mRNA vaccine offers a way of making the immune response more targeted by using the individual tumor’s molecular characteristics to identify the abnormal signals that the immune system should recognize,” Prof. Jyoti Bajpai, Director – Medical Precision Immuno-Oncology, Apollo Hospitals, Mumbai, told HealthandMe.
In the Phase 3 INTerpath-001 trial, the combination met its primary endpoint of recurrence-free survival (RFS) and a key secondary endpoint of distant metastasis-free survival (DMFS).
Compared with Keytruda alone, the combination of intismeran autogene and Keytruda showed statistically significant and clinically meaningful improvements in both RFS and DMFS.
The findings were reported in patients with stage IIB, IIC, III, or IV cutaneous melanoma who had undergone complete surgical removal of their cancer and had not previously received systemic therapy.
After tumor sequencing, up to ~34 patient-specific neoantigens are encoded into a single mRNA construct delivered in lipid nanoparticles.
Host cells translate the neoantigens, which are then presented on MHC, driving de novo and expanded neoantigen-specific CD8+ and CD4+ T-cell responses.
When combined with PD-1 blockade, the vaccine supplies the antigenic “signal” while the checkpoint inhibitor supplies the “permission” to attack.
“The result is a more focused, polyclonal, and potentially longer-lived anti-tumor immune response—exactly what is needed to clear residual microscopic disease after resection,” Dr. Shyam Aggarwal, Chairman, Medical Oncology, Sir Ganga Ram Hospital, told HealthandMe.
Early translational data from KEYNOTE-942 already showed durable neoantigen-specific T-cell responses, supporting the idea that the vaccine can generate immune memory that outlasts the treatment period.
“Immunotherapy releases the body’s natural brakes to attack cancer, whereas the custom vaccine acts like a precision GPS—training the immune system to recognize the unique genetic signature of that patient's specific tumour. Immunotherapy mobilizes the immune response, but the vaccine tells it exactly where to go,” Prof. Jyoti said.
“The practical implication is a shift in the adjuvant paradigm: rather than relying solely on broad immune checkpoint inhibition or chemotherapy, we can now envision adding a tumor-specific ‘instruction set’ that educates the patient’s own T-cell repertoire against the unique mutational fingerprint of their cancer,” the noted oncologist said.
He added that the manufacturing turnaround, currently ~6 weeks from biopsy to first dose, remains a logistical and cost challenge. However, the COVID-era mRNA infrastructure has shown that rapid, decentralized production of custom constructs is feasible.
India’s cancer burden has continued to rise steadily over the past five years, with the estimated number of new cancer cases increasing from 14.26 lakh in 2021 to 15.70 lakh in 2025, while annual cancer-related deaths also climbed from 7.89 lakh to an estimated 8.69 lakh during the same period, according to data placed before Parliament recently.
For India, this technology has intriguing potential, Dr Jyoti said.
While typical skin melanoma is less common here, India sees higher rates of acral and mucosal subtypes, which tend to be aggressive and diagnosed late.
“A tailored neoantigen approach could be very useful for these complex cases. However, manufacturing costs, long turnaround times for genomic sequencing, and cold-chain logistics mean translating this into routine clinical care in India may take time,” she added.
© 2024 Bennett, Coleman & Company Limited